KPTI vs. WOLF

Last updated Jun 9, 2026

KPTI (Karyopharm Therapeutics Inc.) and WOLF (Wolfspeed, Inc.) are both stocks. KPTI operates in Biotechnology (Healthcare), while WOLF operates in Semiconductors (Technology). At a 0.16 correlation, their price movements are largely independent.

Performance

KPTI vs. WOLF - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Karyopharm Therapeutics Inc. (KPTI) and Wolfspeed, Inc. (WOLF). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, KPTI achieves a 15.49% return, which is significantly lower than WOLF's 218.32% return.

KPTI

• 1D: -6.39%
• 1M: -1.62%
• YTD: 15.49%
• 6M: 44.31%
• 1Y: 89.31%
• 3Y*: -36.47%
• 5Y*: -43.70%
• 10Y*: -23.75%

WOLF

• 1D: 0.65%
• 1M: 18.93%
• YTD: 218.32%
• 6M: 141.90%
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

KPTI vs. WOLF - Yearly Performance Comparison

	2026 (YTD)	2025
KPTI Karyopharm Therapeutics Inc.	15.49%	15.91%
WOLF Wolfspeed, Inc.	218.32%	-21.22%

Correlation

The correlation between KPTI and WOLF is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (All Time) Calculated using the full available price history since Sep 30, 2025	0.16

Fundamentals

Market Cap KPTI : $210.08M WOLF : $21.77B
EPS KPTI : -$13.00 WOLF : -$11.53
PS Ratio KPTI : 0.84 WOLF : 10.68
Total Revenue (TTM) KPTI : $151.12M WOLF : $712.50M
Gross Profit (TTM) KPTI : $145.13M WOLF : -$208.10M
EBITDA (TTM) KPTI : -$93.05M WOLF : -$1.26B

Return for Risk

KPTI vs. WOLF — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KPTI

KPTI Risk / Return Rank: 73
KPTI Sharpe Ratio Rank: 72
KPTI Sortino Ratio Rank: 76
KPTI Omega Ratio Rank: 71
KPTI Calmar Ratio Rank: 74
KPTI Martin Ratio Rank: 75

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KPTI vs. WOLF - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and Wolfspeed, Inc. (WOLF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KPTI	WOLF	Difference
Sharpe ratio: Return per unit of total volatility	0.95	—	—
Sortino ratio: Return per unit of downside risk	1.96	—	—
Omega ratio: Gain probability vs. loss probability	1.22	—	—
Calmar ratio: Return relative to maximum drawdown	1.86	—	—
Martin ratio: Return relative to average drawdown	4.59	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	KPTI	WOLF	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.95	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.46	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.28	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.27	2.34	-2.61

Drawdowns

KPTI vs. WOLF - Drawdown Comparison

The maximum KPTI drawdown since its inception was -99.50%, which is greater than WOLF's maximum drawdown of -58.22%. Use the drawdown chart below to compare losses from any high point for KPTI and WOLF.

Drawdown Indicators

	KPTI	WOLF	Difference
Max Drawdown Largest peak-to-trough decline	-99.50%	-58.22%	-41.28%
Max Drawdown (1Y) Largest decline over 1 year	-48.36%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-89.32%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-98.36%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-99.15%	—	—
Current Drawdown Current decline from peak	-98.80%	-24.60%	-74.20%
Average Drawdown Average peak-to-trough decline	-75.28%	-34.87%	-40.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.53%	—	—

Volatility

Volatility by Period

	KPTI	WOLF	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.86%	—	—
Volatility (6M) Calculated over the trailing 6-month period	62.32%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	94.32%	120.69%	-26.37%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	94.91%	120.69%	-25.78%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	86.51%	120.69%	-34.18%

Dividends

KPTI vs. WOLF - Dividend Comparison

Neither KPTI nor WOLF has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

KPTI vs. WOLF - Profitability Comparison

The chart below illustrates the profitability comparison between Karyopharm Therapeutics Inc. and Wolfspeed, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

KPTI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a gross profit of 33.72M and revenue of 35.07M. Therefore, the gross margin over that period was 96.2%.

WOLF - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Wolfspeed, Inc. reported a gross profit of -27.00M and revenue of 150.20M. Therefore, the gross margin over that period was -18.0%.

KPTI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported an operating income of -26.76M and revenue of 35.07M, resulting in an operating margin of -76.3%.

WOLF - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Wolfspeed, Inc. reported an operating income of -101.30M and revenue of 150.20M, resulting in an operating margin of -67.4%.

KPTI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a net income of -22.39M and revenue of 35.07M, resulting in a net margin of -63.9%.

WOLF - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Wolfspeed, Inc. reported a net income of -119.90M and revenue of 150.20M, resulting in a net margin of -79.8%.

Frequently Asked Questions

Can I hold both KPTI and WOLF in my portfolio?

KPTI and WOLF have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.